Bayer's US Pharma Ambitions Collide With Courtroom Risks and Pricing Politics

Bayer stock falls to EUR 43.91 as a fresh Roundup trial begins in Missouri, with roughly 65,000 US claims still unresolved and a USD 7.25 billion settlement undecided.

Bayer shares slipped 2.5% on Monday to EUR 43.91, leaving the stock hovering just above its 200-day moving average of EUR 43.13. The decline reflects a familiar tug-of-war for investors: the company's bold American expansion on one side, and a stubborn legal overhang on the other.

Fresh Roundup Trial Opens in Missouri

A new trial over the weedkiller Roundup got underway in Missouri, where three plaintiffs accuse Bayer subsidiary Monsanto of inadequate product testing and faulty design. Roughly 65,000 claims remain unresolved in the United States, according to Reuters, making the case a key gauge of how much exposure lingers after a prior US Supreme Court ruling.

The market is also awaiting clarity on the financial scale of those liabilities. A hearing on a proposed settlement worth USD 7.25 billion took place on September 14, but as of the latest Reuters reports, a court decision on the deal had yet to arrive.

Those unresolved Monsanto-era obligations continue to weigh on sentiment even as management pushes ahead with a broader overhaul. Part of that effort includes a USD 2.2 billion investment in a pharmaceutical production site in Ohio.

A Strategic Bet on America

Bayer's pharma business is increasingly tilting toward North America. The US now accounts for 35% of global pharma revenue, up from roughly 20% in 2018, and the company aims to double that business by the end of the decade.

CEO Bill Anderson has described the United States as an indispensable pillar for both manufacturing and innovation. The pivot comes alongside a sweeping staffing overhaul: headcount has fallen substantially in recent years as administrative layers have been trimmed, shifting resources away from top-heavy bureaucracy and toward targeted spending on high-margin therapies.

The Ohio campus embodies that strategy, consolidating active ingredient and finished-drug production at a single location. Capacity is concentrated in oncology as well as cardiovascular and kidney disease. Planned output includes Kerendia for kidney disease, Nubeqa for prostate cancer, and the development candidate Asundexian for stroke prevention. In the five years preceding the project, Bayer had already channeled more than USD 7 billion into US pharma research and manufacturing.

Washington Turns Up the Heat on Drug Prices

Concentrating so heavily on overseas markets carries margin risk. US drug prices remain well above those in other Western nations—in some cases nearly triple. President Donald Trump has pressed hard for meaningful cuts on the home market while simultaneously pushing for higher prices abroad.

Should political pressure bite into US reimbursement rates, one of Bayer's central growth promises would face a stern test.

Analysts Split on the Near-Term Picture

Attention is now shifting to operating performance ahead of the next earnings report. Bayer plans to release third-quarter 2026 results on November 3 at 07:30 CET.

Two research houses have weighed in. On September 29, Deutsche Bank Research analyst Virginie Boucher-Ferte rated the stock "Buy" with a price target of EUR 60, reportedly expecting operating revenue growth of 1.3% year over year in the quarter while forecasting a 10% decline in operating profit.

Last Thursday, JPMorgan analyst Richard Vosser reaffirmed an "Overweight" rating and a EUR 61 price target. In his view, early market expectations for the third quarter were set too high, a call he attributed largely to timing effects in the agricultural business.

The stock has gained 20% year to date despite recent consolidation, trading at EUR 44.56 in Monday's session—a valuation that reflects both the promise of the US buildout and the uncertainty that still shadows it.